What is the latest price of a box of Trelagliptin?

Trelagliptin (Trelagliptin) is a new type of dipeptidyl peptidase-4 (DPP-4) inhibitor, developed by Takeda Pharmaceutical Company of Japan. It is mainly used to treat type 2 diabetes . The unique feature of this drug is that it only needs to be taken once a week, which greatly improves patients' medication compliance and life convenience compared with traditional daily anti-diabetic drugs. Trelagliptin inhibits the activity of DPP-4 enzyme in the body and prolongs the action time of endogenous glucagon-like peptide-1 (GLP-1), thereby promoting insulin secretion, inhibiting glucagon release, and helping patients maintain stable blood sugar levels. Because of its mild effect, low risk, and difficulty in causing hypoglycemia, it is regarded as a safe and long-term oral hypoglycemic solution overseas.

Currently, the original drug of trotagliptin has not been officially approved for marketing in mainland China. Therefore, it is not available for purchase in domestic pharmacies and hospitals, and it cannot be included in the scope of medical insurance reimbursement. However, the drug has been widely used in Japan and other places and has received good clinical feedback. In overseas markets, a box of 50mg 20-tablet trolagliptin original medicine sells for about RMB 1,000 to 1,200 yuan per box. For a 100mg 20-piece box, the price can be as high as more than RMB 2,000 yuan. Price differences mainly come from factors such as drug specifications, sales channels and local tax rates.

In addition, some countries have launched generic versions, such as Laos version, Bangladesh version, etc. The main ingredients are the same as the original drug, the efficacy is equivalent but the price is more affordable. The price of the Lao version of troagliptin ranges from RMB 100 to RMB 600, depending on specifications and channels. Generic drugs are highly consistent with original drugs in formula and dosage, making them an alternative choice for some overseas patients.

Trelagliptin is considered to be one of the major developments in the field of DPP-4 inhibitors due to its long-acting, low-risk and strong compliance characteristics. It not only simplifies the medication process for type 2 diabetes, but also makes long-term blood sugar management easier and more stable.

Reference materials:https://en.wikipedia.org/wiki/Trelagliptin